EFdA-TP 

EFdA-TP is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP inhibits HIV-1 RT with multiple mechanisms^[1].

EFdA-TP (0.05-10 μM; for 15 min) inhibits RT-catalyzed DNA synthesis as an ICT or DCT^[1].
EFdA-TP can block RT as a translocation-defective RT inhibitor that dramatically slows DNA synthesis, acting as a de facto immediate chain terminator. EFdA-TP can function as a delayed chain terminator, allowing incorporation of an additional dNTP before blocking DNA synthesis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

533.19

C₁₂H₁₅FN₅O₁₂P₃

950913-56-1

O=[P](O[P](O[P](O)(O)=O)(O)=O)(O)OC[C@]1(O[C@@](C[C@@H]1O)([H])N2C3=NC(F)=NC(N)=C3N=C2)C#C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Eleftherios Michailidis, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289(35):24533-48.  [Content Brief]

  [2]. Martin Markowitz, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. Curr Opin HIV AIDS. 2018 Jul;13(4):294-299.  [Content Brief]